Identification of extrastriatal dopamine D2 receptors in post mortem human brain with [125I]epidepride.
The regional distribution of striatal and extrastriatal dopamine D2 receptors in human brain was studied in vitro with (S)-N-[(1-ethyl-2- pyrrolidinyl)methyl]-5-[125I]iodo-2,3-dimethoxybenzamide, [125I]epidepride, using post mortem brain specimens from six subjects. Scatchard analysis of the saturation equilibrium binding in twenty-three regions of post mortem brain revealed highest levels of binding in the caudate (16.5 pmol/g tissue) and putamen (16.6 pmol/g tissue) with lower levels seen in the globus pallidus (7.0 pmol/g tissue), nucleus accumbens (7.2 pmol/g tissue), hypothalamus (1.8 pmol/g tissue), pituitary (1.3 pmol/g tissue), substantia innominata (1.0 pmol/g tissue), and amygdala (0.87 pmol/g tissue). Of note was the presence of dopamine D2 receptors in the four thalamic nuclei studied, i.e. anterior nucleus (1.0 pmol/g tissue), dorsomedial nucleus (0.96 pmol/g tissue), ventral nuclei (0.72 pmol/g tissue), and pulvinar (0.86 pmol/g tissue), at levels comparable to the amygdala (0.87 pmol/g tissue) and considerably higher than levels seen in anterior cingulate (0.26 pmol/g tissue) or anterior hippocampus (0.36 pmol/g tissue). The frontal cortex had very low levels of dopamine D2 receptors (0.17-0.20 pmol/g tissue) while the inferior and medial temporal cortex had relatively higher levels (0.31-0.46 pmol/g tissue). Inhibition of [125I]epidepride binding by a variety of neurotransmitter ligands to striatal, ventral thalamic and inferior temporal cortical homogenates demonstrated that [125I]epidepride binding was potently inhibited only by dopamine D2 ligands. The present study demonstrates that dopamine D2 receptors are present in basal ganglia, many limbic regions, cortex and in the thalamus. The density of thalamic D2 receptors is comparable to many limbic regions and is considerably higher than in cortex.(ABSTRACT TRUNCATED AT 250 WORDS)
Kessler
R M
RM
Department of Radiology, Vanderbilt University School of Medicine, Nashville, TN 37232.
Whetsell
W O
WO
Ansari
M S
MS
Votaw
J R
JR
de Paulis
T
T
Clanton
J A
JA
Schmidt
D E
DE
Mason
N S
NS
Manning
R G
RG
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000368:Aged; D000369:Aged, 80 and over; D001549:Benzamides; D001923:Brain Chemistry / Q000187:drug effects*; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism; D003342:Corpus Striatum / Q000378:metabolism; D004146:Dioxanes / Q000494:pharmacology; D006801:Humans; D019329:Idazoxan; D066298:In Vitro Techniques; D007457:Iodine Radioisotopes; D007700:Kinetics; D008032:Limbic System / Q000187:drug effects / Q000378:metabolism; D008297:Male; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2 / Q000032:analysis / Q000378:metabolism*; D013788:Thalamus / Q000187:drug effects / Q000378:metabolism
D000317:Adrenergic alpha-Antagonists; D001549:Benzamides; D004146:Dioxanes; D007457:Iodine Radioisotopes; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2; C063525:epidepride; D019329:Idazoxan